ACHONDROPLASIA
Clinical trials for ACHONDROPLASIA explained in plain language.
Never miss a new study
Get alerted when new ACHONDROPLASIA trials appear
Sign up with your email to follow new studies for ACHONDROPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a weekly shot help children with achondroplasia grow taller?
Disease control CompletedThis phase 2 trial is testing an experimental drug called TransCon CNP in children with achondroplasia, a common form of dwarfism. The study aims to see if a once-weekly injection under the skin can safely improve growth, measured by height velocity over a year. Participants will…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: Visen Pharmaceuticals (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can growth hormone boost height in children with dwarfism?
Disease control CompletedThis trial is testing whether daily injections of recombinant human growth hormone can improve growth in children with achondroplasia, a genetic condition that causes short stature. The study will include children aged 2 to 10 who have not previously been treated with growth horm…
Matched conditions: ACHONDROPLASIA
Phase: PHASE4 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New weekly injection shows promise for boosting growth in kids with dwarfism
Disease control CompletedThis study tested a once-weekly injection called TransCon CNP in 84 children aged 2 to 11 with achondroplasia, the most common form of dwarfism. The goal was to see if it safely increases growth rate over a year compared to a placebo. After the first year, all children could rece…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2, PHASE3 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Weekly shot may boost growth in kids with dwarfism
Disease control CompletedThis study tests a weekly injection called TransCon CNP in children aged 2 to 10 with achondroplasia, the most common form of dwarfism. The goal is to see if it can safely improve growth over one year. Half the children receive the drug and half receive a placebo, and all childre…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: Ascendis Pharma A/S • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug shows promise for boosting growth in kids with dwarfism
Disease control CompletedThis study tested a daily oral drug called infigratinib in 114 children aged 3 to 18 with achondroplasia, the most common form of dwarfism. The goal was to see if it could safely increase their growth rate compared to a placebo. The trial is now complete, and results will show wh…
Matched conditions: ACHONDROPLASIA
Phase: PHASE3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug shows promise for boosting growth in kids with dwarfism
Disease control CompletedThis study tested an oral drug called infigratinib in 84 children aged 3 to 11 with achondroplasia, the most common form of dwarfism. The goal was to see if it could safely increase their growth rate. Children took the drug daily, and researchers measured height changes and side …
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
No treatment, just tracking: PROPEL study watches how kids with achondroplasia grow
Knowledge-focused CompletedThis study followed 271 children with achondroplasia, ages 2.5 to 17, to understand their growth, medical issues, and quality of life over time. No medication or treatment was given. The goal was to gather natural history data to help design future clinical trials.
Matched conditions: ACHONDROPLASIA
Sponsor: QED Therapeutics, a BridgeBio company • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC